BriaCell reports overall survival, clinical benefit data at ASCO 2025

BriaCell (BCTX) Therapeutics presents clinical data in three clinical poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology Annual Meeting. BriaCell has featured robust survival and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical progress data from its ongoing pivotal Bria-IMT Phase 3 study and Phase 1/2 study of Bria-OTS in metastatic breast cancer. Poster Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer: “Trial in Progress” poster presents early enrollment data and the overall design of the Phase 3 pivotal trial along with updated clinical outcomes from the Phase 2 Bria-IMT study. Poster Title: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer: In the Phase 2 study of Bria-IMT combined with an immune checkpoint inhibitor in 54 heavily pre-treated metastatic breast cancer patients, Bria-IMT demonstrated promising efficacy and safety. Notably, 44% of patients had failed a prior antibody-drug conjugate, and 20% had failed a prior CPI. Among these patients, the overall clinical benefit rate was 55%, with CBRs of 100% in HER2+, 55% in HR+/HER2-, and 45% in triple-negative breast cancer subgroups, indicating antitumor activity across MBC subtypes. Additionally, patients treated with the selected Phase 3 formulation experienced significantly improved overall survival compared to those receiving the alternate formulation, highlighting the potential of Bria-IMT for advancing in clinical development. The efficacy data and favorable safety profile of the Phase 3 formulation support the continued evaluation of Bria-IMT in BriaCell’s ongoing pivotal Phase 3 trial, which compares Bria-IMT to the treatment of physician’s choice. The ongoing patient subset analysis in this trial aims to identify the patients who may derive the greatest benefit from Bria-IMT treatment. Poster Title: Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer. Type and Title: Poster Session – Breast Cancer-Metastatic In a dose-escalation Phase 1/2 study, heavily pre-treated MBC patients received Bria-OTS monotherapy. The Phase 1 segment enrolled and treated 3 patients with the first patient achieving a confirmed resolution of a breast cancer lung metastasis and remaining on study with single agent Bria-OTS. Following successful completion of safety evaluations, BriaCell has initiated the combination cohort dosing the first patient with Bria-OTS plus checkpoint inhibitor.